Giuseppe
Emeritus
Vaccine. 2009 Jun 21. [Epub ahead of print]
Vaxfectin((R)), a cationic lipid-based adjuvant for protein-based influenza vaccines.
Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, Vilalta A, Wei Q, Rolland A, Smith LR. Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121-4340, USA.
Mice were immunized either with unadjuvanted seasonal trivalent influenza vaccine (TIV) or TIV formulated with Vaxfectin((R)), a cationic lipid-based adjuvant. Increasing doses of Vaxfectin((R)) resulted in increased hemagglutination-inhibition or anti-TIV ELISA titers, with up to a 200-fold increase obtained with 900mug of Vaxfectin((R)). A >/=10-fold dose-sparing effect was demonstrated with Vaxfectin((R)) formulations. Vaxfectin((R)) preferentially increased IgG2 titers compared to IgG1 titers, resulting in a balanced IgG isotype distribution. Lower doses of Vaxfectin((R)) (30mug) did not enhance antibody responses, but increased the number of IFN-gamma secreting T-cells by up to 18-fold. The data demonstrate that Vaxfectin((R)) enhances Th1 responses with protein-based seasonal influenza vaccine, and suggest that cellular or humoral immune responses may be preferentially induced by modifying the Vaxfectin((R)):antigen ratio in the vaccine formulation.
PMID: 19552895 [PubMed - as supplied by publisher]
-
------
Vaxfectin((R)), a cationic lipid-based adjuvant for protein-based influenza vaccines.
Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, Vilalta A, Wei Q, Rolland A, Smith LR. Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121-4340, USA.
Mice were immunized either with unadjuvanted seasonal trivalent influenza vaccine (TIV) or TIV formulated with Vaxfectin((R)), a cationic lipid-based adjuvant. Increasing doses of Vaxfectin((R)) resulted in increased hemagglutination-inhibition or anti-TIV ELISA titers, with up to a 200-fold increase obtained with 900mug of Vaxfectin((R)). A >/=10-fold dose-sparing effect was demonstrated with Vaxfectin((R)) formulations. Vaxfectin((R)) preferentially increased IgG2 titers compared to IgG1 titers, resulting in a balanced IgG isotype distribution. Lower doses of Vaxfectin((R)) (30mug) did not enhance antibody responses, but increased the number of IFN-gamma secreting T-cells by up to 18-fold. The data demonstrate that Vaxfectin((R)) enhances Th1 responses with protein-based seasonal influenza vaccine, and suggest that cellular or humoral immune responses may be preferentially induced by modifying the Vaxfectin((R)):antigen ratio in the vaccine formulation.
PMID: 19552895 [PubMed - as supplied by publisher]
-
------